Linezolid Kabi

Linezolid, the active ingredient in Linezolid Kabi, is an oxazolidinone presented as an injectable solution for intravenous use. It treats serious bacterial infections such as skin and soft tissue infections, community‑acquired pneumonia, hospital‑acquired pneumonia and methicillin‑resistant Staphylococcus aureus (MRSA) infections in adult patients.

GNH USA supplies Linezolid Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Linezolid is an oxazolidinone antibiotic used to treat infections caused by Gram‑positive bacteria, including resistant strains.

- Skin and soft tissue infections: provides effective coverage against MRSA and other Gram‑positive pathogens. - Community‑acquired pneumonia: offers activity against resistant Streptococcus pneumoniae. - Hospital‑acquired pneumonia: active against multidrug‑resistant organisms in nosocomial settings. - MRSA infections: eradicates methicillin‑resistant Staphylococcus aureus in systemic and localized disease.

Adverse reactions may occur with linezolid therapy and are categorized by frequency.

Common Side Effects: - Nausea - Diarrhea - Headache - Metallic taste

Serious or Rare Side Effects: - Thrombocytopenia - Peripheral neuropathy - Serotonin syndrome

Linezolid requires careful monitoring in several clinical situations.

- Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: assess liver enzymes regularly. - Concomitant serotonergic agents: avoid due to risk of serotonin syndrome. - Hematologic monitoring: perform routine complete blood counts. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Linezolid can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs): risk of serotonin syndrome. - Serotonin‑norepinephrine reuptake inhibitors (SNRIs): increased serotonin toxicity. - Monoamine oxidase inhibitors (MAOIs): potentiate serotonergic effects.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce linezolid plasma concentrations. - Warfarin: potential alteration of INR, requiring coagulation monitoring.